Fluoxetine vs. Nortriptyline in preventing post-stroke depression


Phase N/A Results

Trial Description

To compare the prophylactic efficacies of an SSRI (fluoxetine) and a tricyclic antidepressant (nortriptyline) against post-stroke depression.


  • Fluoxetine (ProzacĀ®)Drug
    Other Names: Patients receiving fluoxetine
    Intervention Desc: Selective serotonin reuptake inhibitor
  • Nortriptyline (Pamelor)Drug
    Intervention Desc: (theoretical) Nortriptyline, a tricyclic antidepressant, blocks the reuptake of norepinephrine and serotonin in the central nervous system. Like all secondary-amine tricyclics, nortriptyline blocks norepinephrine more strongly than it does serotonin.

Trial Design

Longitudinal, double-blind, randomized, placebo-controlled trial

Patient Involvement

48 non-depressed poststroke patients were divided into 3 groups: a placebo group (N=15), a fluoxetine group (N=13), and a nortriptyline group (N=13 at 3 months). Patients received treatment for 3 months, during which time they were regularly screened for depression. All patients were treated and evaluated in a double-blind fashion. At the end of the third month, treatment was discontinued, and a 21-month follow-up period commenced, during which the patients were also regularly screened for depression.


Type Measure Time Frame Safety Issue
Primary Minor post-stroke depression